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Summary EMT6 multicellular spheroids were introduced into the peritoneal cavities of mice and allowed to
become vascularised, resulting in solid spherical tumours. The necrotic cores of the initially avascular
spheroids were replaced by vascularised tumour tissue but the outer zones of the spheroids failed to become
vascularised. The presence of both vascular and avascular components in each spheroid allowed the role of the
vasculature in the antitumour action of flavone acetic acid (FAA) to be determined. Eighteen hours after
treatment with FAA 0.8 mmol kg-', the vascularised core became necrotic and haemorrhagic, while the outer
avascular zone remained viable. Tumour cells which were infiltrating superficial sub-mesothelial fat did not
become necrotic despite the presence of numerous thrombi in associated vessels. Injection of two fluorescent
vascular markers, the first (Hoechst 33342) together with FAA, and the second (10-nonyl acridine orange) 4 h
later, demonstrated that there is a marked loss of blood flow in the spheroids. These results provide further
evidence that FAA kills blood vessel-dependent tumour cells by interrupting the tumour blood supply.
Flavone acetic acid (FAA) is a synthetic flavonoid with
broad spectrum activity against solid murine tumours and
human xenografts in mice. This experimental agent is con-
tinuing to generate interest despite disappointing results in
clinical trials (Kerr et al., 1989) because it appears to act via
a novel, indirect mechanism. The low cytotoxicity of FAA
against cell lines from FAA-responsive tumours (Finlay et
al., 1988), suggests that its antitumour effect involves some
interaction with host tissues. FAA affects both tumour struc-
ture and physiology, including haemorrhagic necrosis (Smith
et al., 1987), a fall in ATP levels (Evelhoch et al., 1988), and
a decrease in blood flow (Evelhoch et al., 1988; Bibby et al.,
1989a). Recently we showed that this fall in tumour blood
flow is progressive and irreversible, beginning within 15
minutes of FAA administration. Blood flow appeared to be
important in tumour cell killing, because avascular in-
traperitoneal EMT6 multicellular spheroids were much more
resistant to the cytotoxic action of FAA than were vas-
cularised intramuscular EMT6 tumours, even when the drug
was administered by the intraperitoneal route (Zwi et al.,
1989).
While the resistance of spheroids to FAA in the above
study was attributed to their lack of blood vessels, other site-
or size-related factors could not be excluded. It has been
suggested that the site of the tumour is important in determ-
ining its responsiveness to FAA (Bibby et al., 1989b). Finlay
et al. (1988) found that small lung metastases of the Lewis
lung tumour failed to respond to FAA treatment, while
larger lung nodules and subcutaneous implants of this
tumour were sensitive. To determine the role of the vas-
culature in the anti-tumour action of FAA, we have
examined the process of attachment and vascularisation of
EMT6 spheroids in the peritoneum, and found tumours
which were directly comparable in site and size range to
avascular spheroids (AVS). Since these vascularised spheroids
(VS) were themselves composed of a vascularised core sur-
rounded by an avascular outer layer, direct comparison of
the effects of FAA on vascular and avascular tissue within
the same individual tumour was possible. The histological
changes occurring in AVS, VS and small deposits of
infiltrating tumour have been compared 18 h after treatment.
A double-label fluorescent vascular dye technique, based on
that developed by Trotter et al. (1989), was used to assess the
changes in blood flow in the VS at 4 h.
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Materials and methods
Histological studies
EMT6 multicellular tumour spheroids were grown in spinner
flask culture in a-MEM + 10% fetal calf serum, and between
15 and 25 spheroids, varying in size from 0.5 to 1.2mm in
diameter, were injected into the peritoneal cavities of anaes-
thetised Balb/C mice through a 161 gauge needle, as de-
scribed previously (Zwi et al., 1989). Seven days later the
mice in the treatment group (n = 7) were injected with FAA
0.8 mmol kg-' (kindly supplied by Dr K.D. Paull, National
Cancer Institute) in 5% w/v sodium bicarbonate by the
intravenous (i.v.) or intraperitoneal (i.p.) route, and were
killed after a further 18 h. Untreated spheroid-bearing mice
(n = 2) were killed after the same interval. The peritoneal
cavities of the mice were opened, the free spheroids were
collected, and those spheroids which had become attached to
host structures were excised with a cuff of adjacent tissue.
The spheroids were fixed in either 4% neutral formaldehyde
or 2.5% phosphate buffered glutaraldehyde (pH 7.4). The
formalin-fixed tissue was embedded in paraffin, and 5gm
sections were stained with haematoxylin and eosin (H&E).
The glutaraldehyde-fixed spheroids were embedded in epoxy
resin and 2gim sections stained with toluidine blue. Multiple
sections were examined from each spheroid.
Bloodflow studies
Eight days after introduction of spheroids into the peritoneal
cavity, three mice received two i.v. injections. The first con-
tained the sodium salt of FAA (8 mM), Hoechst 33342
(2 mgml-') (H33342) (Serva Fine Chemicals, Westbury, NY,
USA) and 5% w/v D-glucose. The volume injected was
0.01 ml per gram body weight (FAA dose 0.8 mmolkg-').
The second injection, given 4h later, contained 2 mM 10-
nonyl acridine orange (NAO) (Molecular Probes Inc.,
Eugene, OR, USA), 4% v/v dimethylsulphoxide (DMSO)
and 5% w/v D-glucose, and was given at an NAO dose of
20 mm kg-'. In control mice (n = 3), the first injection con-
tained only H33342. The mice were killed 5 minutes after the
second injection and the attached spheroids excised and
rapidly frozen in liquid nitrogen-cooled Freon 12 (E.I. Du
Pont de Nemours & Co. Inc., Wilmington, DE, USA).
Frozen sections 10 or 16jim in thickness were cut at
160-200jam intervals, and viewed under a Nikon Optiphot
microscope with an EF-D Episcopic fluorescence attachment,
using filter blocks UV1A (excitation maximum 365 nm, bar-
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rier 400 nm) and B2A (excitation maximum 450-480 nm,
barrier 520 nm) to visualise the staining by H33342 and
NAO respectively. Sections were viewed dry or mounted in
10% v/v glycerol saline.
Results
Histological appearances ofuntreated spheroids
Eight days after the introduction of EMT6 spheroids into the
peritoneal cavities of mice, there was mild abdominal disten-
sion by blood-stained ascites. More than half of the intro-
duced spheroids were recovered from each mouse, and about
20% of these were attached to host tissues, and appeared as
cream-coloured spherical or ellipsoidal protrusions varying in
size from barely visible to 4 mm in diameter. These were
adherent to the peritoneal surfaces of the anterior abdominal
muscles, the diaphragm, the omentum and mesenteries. A
frequent site of attachment was the needle track through
which the spheroids had been introduced. None of the
spheroids was haemorrhagic. The majority of the attached
spheroids were vascularised, and between one and 11 vas-
cularised spheroids were found in each mouse.
Avascular spheroids, whether free or attached, were com-
posed of an outer zone of viable spindle-shaped cells,
145 ± 12 jim (s.e.m., n = 8) thick, surrounding an inner nec-
rotic zone, which consisted of disintegrating cytoplasmic and
nuclear material (Figure 1a). Scattered macrophages,
identified by their smaller size, indented nuclei and more
marginated chromatin, were distributed evenly in the viable
zone.
Figure 1 Histology of avascular (AVS) and vascularised
spheroids (VS) (a) AVS consisting of an outer layer of spindle-
shaped tumour cells (0), and an inner zone of necrotic cells (I).
(b) VS consisting of spindle cells with no evidence of necrosis.
Blood vessels (arrows) are present in the inner zone (I), but not
the outer zone (0). (c) VS showing attachment to the peritoneal
surface and underlying skeletal muscle. Some tumour cells
(arrows) are infiltrating within the muscle and mesothelium. (d)
Spheroid in which the process of vascularisation appears incom-
plete. Blood vessels and loosely-packed tumour cells occupy part
of the core (V), while a small, lens-shaped necrotic zone (N)
persists below the outer viable zone (0). (a-c) H&E-stained
paraffin sections; (d) toluidine blue-stained plastic section.
Bar = 20 iLm.
Most vascularised spheroids were composed of a solid
mass of tumour cells and showed no evidence of central
necrosis (Figure lb,c). Blood vessels were present in their
central regions, but never in the outer zone. The mean dis-
tance from the spheroid surface to the most superficial vessel
in each spheroid was 142 ± 10jim (s.e.m., n = 7), correspon-
ding to the thickness of the viable zone of the AVS. In a few
spheroids, the central zone showed features of both VS and
AVS with tumour cells and blood vessels near the pole
adjacent to the attachment site, and necrotic material
towards the unattached pole (Figure Id). These appearances
were interpreted as incomplete vascularisation (Figure 6c).
Host cells were evenly dispersed within the VS by light and
electron microscopy, including macrophages, fibroblasts, lym-
phocytes and granulocytes. Small groups of tumour cells
were seen in the adjacent host tissues including skeletal
muscle (Figure ic) and peritoneal fat, usually near the point
of attachment of a spheroid. These infiltrative tumour
deposits differed from VS in having a high vascular density
and vessels close to the peritoneal surface. Several such areas
were present in each mouse.
Fluorescent bloodflow markers in untreated VS
Attached spheroids were excised 5 minutes after simultaneous
administration of both H33342 and NAO. Both dyes stained
the tumour cells located within five cell diameters of the
blood vessels, H33342 staining the nuclei and NAO the
cytoplasm (Figure 2a,b). The diffusion distances of the two
dyes from the vessels was initially similar whether viewed wet
or dry, but within 15 minutes wet-mounted sections showed
progressive diffusion of NAO into previously unstained
areas. The pattern of staining with H33342 was more stable,
but when given 4 h before sacrifice, diffusion in vivo caused
most cells in the VS to show some fluorescence, although the
paravascular cells remained brightest (Figure 2c).
Both dyes identified the site of functional blood vessels in
the central regions of the VS. An outer rim of non-
fluorescent tissue, varying in thickness, but usually less than
140jim, confirmed the histological observations that this
zone was avascular (Figure 2). Weakly fluorescent cells at the
surface of VS (Figure 2a,b), were also present on both the
free and adherent AVS, and were assumed to be due to
staining via the peritoneal fluid.
In the untreated VS, vessels identified by one fluorescent
marker were invariably also stained by the other, even when
the dyes were injected 4 h apart, indicating that no opening
or closure of tumour vessels occurred during this period.
Adjacent host tissues showed confluent staining by both dyes
(Figures 2c,d; Sc), presumably due to their high capillary
density.
The histological appearances ofspheroids after FAA treatment
Mice were treated with FAA i.v. or i.p. 7 days after introduc-
tion of EMT6 spheroids into the peritoneal cavities, and the
free and attached spheroids, were examined histologically
after 18 h. Treated AVS had thinner rims of viable cells
(90 ± 2 iLm s.e.m., n = 49) than did untreated AVS
(145 ± 12;jm, s.e.m., n = 8), but were otherwise indistin-
guishable.
Treated VS appeared red in colour. All 25 VS examined
histologically showed similar changes regardless of size
(0.4-4 mm in diameter). The central zone showed haemorr-
hage, margination of chromatin, nuclear pyknosis, and
fragmentation of nuclei and cytoplasm (Figure 3). Small
residual islands of apparently viable tumour cells were found
in the centres of five VS. The outer avascular zones of all
treated VS were composed of cells identical in appearance to
those of untreated VS (Figure 3), with fine chromatin and
mitotic activity, but measured only 60 ± 4jLm (s.e.m.,
n = 16) in thickness. The changes were the same whether the
FAA was administered i.v. or i.p.
The central necrotic zones of treated VS differed from
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Figure 2 Fluorescent staining of untreated VS. (a,b) Staining of
paravascular tumour cell nuclei by H33342 (a) and cytoplasm by
NAO (b) (arrows), both given 5 minutes before sacrifice. The
avascular zone (A) shows no fluorescence except at the surface
(arrowheads). (c,d) VS with underlying peritoneal fatty tissue.
H33342 injected 4 h. and NAO 5 minutes before sacrifice.
H33342 fluorescence (c) is more diffuse after 4 h, but the position
of a vessel (arrow) can still be determined by the brighter
fluorescence. The avascular zone (A), is faintly fluorescing in this
section. The pattern of NAO staining (d) is similar, indicating
that the vessel is still functioning after 4 h. The fatty tissue (F)
stains evenly with both dyes, intense in the case of NAO. 16 jsm
air-dried frozen sections, viewed with UV1A (b,c) and B2A (a,d)
fluorescence filter blocks. Bar = 50 iLm.
blood cells were present dispersed among the necrotic debris
and in congested vessels (Figure 3c,d). In addition, the nec-
rotic process was less advanced in treated VS, with less
degradation and dissolution of the nuclei and cytoplasm of
the dead tumour cells. These distinctions were clearly evident
in the few incompletely vascularised spheroids from treated
animals, where the two types of necrotic zone were con-
tiguous (Figure 3c).
The deposits formed by tumour cell infiltration of sub-
mesothelial fat showed similar FAA-induced changes to
those seen in VS. In superficial zones, where tumour cells
were growing close to the mesothelium, necrosis was rare
despite the presence of numerous thrombi in associated ves-
sels (see below) (Figure 4a,b). However, the deeper masses of
invasive tumour were necrotic (Figure 4a). Fat and skeletal
muscle not infiltrated by tumour did not show necrosis or
thrombosis.
The tumour blood vessels showed a variety ofchanges 18 h
after FAA treatment. The most frequent was congestion,
which was associated with haemorrhage (Figure 3d). Another
was vascular occlusion by fibrin and/or platelet thrombi,
which appeared as amorphous granular or laminated
amphophilic material (Figure 4a,b). Paradoxically, thrombi
Figure 3 Histological changes in VS after FAA treatment. (a)
VS inner core (I) shows haemorrhagic necrosis. The speckled
appearance is due to both scattered red blood cells and pyknotic
tumour cell nuclei, which stain heavily with toluidine blue. The
dead tumour cells are round or oval, while the cells of the outer
viable zone (G) are spindle-shaped. (b) Higher magnification from
the same section as (a) showing the inner zone (I) with cell
fragmentation (arrows) and extravasation of red blood cells
(arrowheads). (c) Incompletely-vascularised spheroid after FAA
treatment. The outer viable zone (G) extends the length of the
photomicrograph. The upper part of the field is not vascularised
and has not been affected by the treatment. This necrotic zone
(N1) lacks blood vessels and haemorrhage, and resembles that of
an AVS (Figure Ia). The lower vascularised portion of the
spheroid contains a necrotic zone (N2) in which cell breakdown is
less advanced. Vessels are packed with red blood cells (arrows).
(d) A higher magnification of the right-hand vessel indicated in
(c), containing red blood cells, which are also seen in the inter-
stitium among the necrotic tumour cells. (a,b) toluidine blue-
stained plastic sections. (c,d) H&E-stained paraffin sections.
Bars = 201Am.
were seen often in tumour regions which did not show nec-
rosis, such as in non-necrotic islands of tissue in the VS
centres and in tumour infiltrating mesenteric fat (Figure 4).
Fluorescent bloodflow markers in FAA-treated VS
An injection of FAA plus H33342 was followed 4 h later by
an injection of NAO. The distribution of H33342 in treated
VS (Figure 5a,c) was similar to that in untreated VS (Figure
2a,c), but NAO staining was totally absent in 13 of the 18 VS
examined (Figure 5b,d), and only an occasional NAO-
positive vessel was seen in the other five VS. The surface
layer continued to show fluorescence with both dyes (Figure
5a,b). Normal tissues taken from the peritoneal cavity
showed both H33342 and NAO staining. However, some loss
of NAO staining was seen in normal tissues close to the
attachment sites of VS (Figure 5d).234 L.J. ZWI et al.
Figure 4 The effect of FAA on a deposit of infiltrating tumour.
(a) A deep nodule of tumour (D) shows necrotic changes, while
the superficial nodule (S) shows numerous vessels distended by
thrombi (arrows). (b) Higher magnification of (a) showing fibril-
lar material in the blood vessels, but an absence of necrosis in
associated tumour cells. H&E-stained paraffin sections.
Bars = 20 gm.
Discussion
By comparing the effects of FAA on vascularised and avas-
cular components of the same tumours, this study has dem-
onstrated the critical role of the tumour vasculature in its
antitumour activity. Lord et al. (1979) first incubated EMT6
multicellular spheroids in the peritoneal cavities of mice to
study the infiltration of host cells. We extended the incuba-
tion time to allow attachment of the spheroids to peritoneal
structures, and for their necrotic cores to be replaced by
blood vessels and viable tumour cells, as illustrated in Figure
Figure 5 Perfusion loss in VS after FAA treatment. Mice were
given FAA and H33342 i.v. at the start of the experiment. NAO
was given after 4 h, 5 minutes before sacrifice. (a) VS consisting
of an avascular zone (A) with surface fluorescence, and a vas-
cularised zone indicated by intense H33342 fluorescence around
vessels (arrows). (b) Same field as (a) showing NAO fluorescence
on the surface of the avascular zone (A), but no fluorescence in
the underlying vascular zone. (c) VS consisting of vascular zone
(V) showing H33342 fluorescence, and the avascular zone (A),
lying on the peritoneal surface and underlying skeletal muscle
(M). (d) Same field as (c) showing NAO fluorescence is absent
from the vascularised core (V), and from much of the adjacent
skeletal muscle (M), indicating failure of perfusion to these
regions. 16jLm air-dried frozen sections, viewed with UVIA (a,c)
and B2A (b,d) fluorescence filter blocks. Bar = 50jm.
6. The experiments were completed before necrosis re-
appeared due to the inadequacy of the vascular supply that
develops with increasing tumour size (Vaupel et al., 1973).
Tumour vascularisation has been extensively studied by
observing the growth of new vessels into implanted tumour
fragments. These observations have identified an early avas-
cular phase of tumour growth, which is followed by vas-
cularisation and accelerated growth (Folkman, 1985). How-
ever, the persistence of a component of the tumour which
remains avascular and dependent entirely on diffusion from
outside the tumour, co-existing with vascularised tumour
tissue, has not been noted previously. The ability to identify
an avascular zone in the VS system by conventional histology
and with i.v. markers probably relates to the symmetrical,
polypoid shape of the tumours, with the vascular supply
passing through only a small region of the spheroid surface.
This mode of growth may be due to resistance of the
peritoneal cavity to spheroid attachment. The frequent
implantation of spheroids at the needle track site supports
this suggestion. In contrast, one would expect that an
angiogenic response from multiple directions into a tumour
implant would obliterate any avascular zone by invading
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Figure 6 Diagram summarising the process of vascularisation of
EMT6 spheroids, and the changes after FAA treatment. (a) Free
avascular spheroid. (b) Attached avascular spheroid. (c) Incom-
pletely vascularised spheroid. (d) Vascularised spheroid. (e) FAA-
treated vascularised spheroid.
The major stimulus for neovascularisation in tumours is
thought to be the production of tumour angiogenic factors
(Presta & Rifkin, 1988). We are not aware of any evidence
that tumour angiogenesis is influenced by oxygen tension.
However, vascularisation in non-tumour tissues occurs as an
adaptive response to hypoxia, as in chick chorio-allantoic
membranes incubated at low oxygen concentrations (Dusseau
& Hutchins, 1988). In addition, the release of a macrophage
angiogenic factor only at low oxygen tension (Knighton et
al., 1983) implies a role for hypoxia in wound-related
angiogenesis. In our experiments, the restriction of neovas-
cularisation to the central zone of the spheroids, suggests
that hypoxia may be necessary for this process in tumours as
well. Macrophages, present in both AVS and VS, may have
been involved. An alternative explanation for the avascular
zone is a loss of angiogenic factors from this zone by
diffusion.
Whatever the explanation, the presence of an avascular
zone could have consequences in studies of drug diffusion, if
a multicellular avascular layer is present in other intra-cavity
solid tumour systems. Los et al. (1989) found different con-
centration gradients of cisplatinum in solid peritoneal CC531
colonic adenocarcinomas after i.v. and i.p. treatments. The
presence of an avascular layer on the peritoneal surface of
the tumour deposits was not excluded, and may have contri-
buted to the higher concentrations found at the tumour
surfaces after i.p. treatment. This could have implications in
the development of i.p. therapies in humans.
The presence of both vascular and avascular tissue in the
same tumours allowed us to examine the role of the vas-
culature in the anti-tumour action of FAA (Figure 6). The
vascularised core of the tumours invariably showed both a
severe loss of perfusion and haemorrhagic necrosis after
FAA treatment. The original outer viable cell layer of the
spheroid, which consistently failed to become vascularised,
remained viable after FAA treatment. There was no
minimum size required for these effects. This is similar to the
finding that vascularised peritoneal tumour deposits regress
after treatment with the angiogenesis inhibitor protamine,
while tumour cells growing as thin avascular layers in the
same animals persist (Heuser et al., 1984). These findings
illustrate both the potential and the limitations of an ap-
proach to tumour treatment based on attacking the tumour
vasculature.
Tumour cell death can occur by various mechanisms in
this spheroid system and these can be differentiated histo-
logically. Central necrosis occurs in tumour cell spheroids of
all types beyond a certain size, and is the result of the
exhaustion of oxygen and other nutrients diffusing in from
the surface, and the accumulation of waste products in the
centre (Sutherland, 1988). This implies that, as the spheroid
grows, dead cells are continually being added to the necrotic
zone and would explain the degree of cellular degradation
seen in the central regions of untreated AVS. A second type
of cell death was seen in the centres of FAA-treated VS. This
appears to result primarily from ischaemia due to vascular
obstruction occurring within 4 h after treatment and results
in a more homogeneous, less advanced degree of cell break-
down than that described above. A third type of cell death
known to occur in this system, is related to FAA but
independent of vascularisation. In a previous study using
similar experimental conditions (Zwi et al., 1989) free EMT6
spheroids did show a significant fall in clonogenic cell yield
after FAA treatment in vivo, though much smaller than that
seen in vascularised intramuscular EMT6 tumours. This is
consistent with the approximately 50% decrease in thickness
of the viable outer zone observed in the present study. This
effect may have been mediated by macrophages, which are
present in the spheroids, and have been shown to be
cytotoxic to tumour cells when exposed to FAA in vitro
(Ching & Baguley, 1988). The histological appearances in the
necrotic and viable areas were similar whether the FAA was
given by the i.v. or i.p. route, and are in agreement with our
earlier studies (Zwi et al., 1989) in which clonogenic cell yield
from peritoneal avascular spheroids was unaffected by route
of administration of FAA.
The distribution of necrosis in VS indicates the role of the
vasculature as the major component of the antitumour action
of FAA. However, the presence of blood vessels alone is not
sufficient, since the highly vascular sub-mesothelial infil-
tration tumour deposits did not undergo necrosis in their
superficial parts despite widespread thrombosis of the associ-
ated vessels. It is possible that thrombosis occurred later in
these regions than in VS allowing insufficient time for the
morphological changes of cell death to develop. A more
likely explanation is that although FAA caused thrombosis
of the vessels, the superficial tumour cells were close enough
to the mesothelial surface for effective metabolite exchange
by diffusion alone. This implies that the major mechanism of
FAA cell killing is acute ischaemia, rather than the release of
a cytotoxic factor by endothelial cells. Furthermore, the high
vascular densities seen in normal sub-mesothelial fat, the
diffuse mode of tumour cell infiltration, and the presence of
vessels very close to the mesothelial surface, all suggest that
the vessels involved were pre-existing host vessels incor-
porated into the tumour during its infiltrative growth. An
implication would be that FAA tumour selectivity (demon-
strated by a lack of necrosis or thrombosis in non-tumour
tissues) resides in the association of blood vessels with
tumour cells and/or their accompanying immune effector
cells, rather than in some peculiarity of the new tumour
vessels themselves.
FAA causes a coagulopathy in mice soon after administra-
tion (Murray et al., 1989), but thrombosis of tumour vessels
has not been reported previously. Thrombi were seen in
vessels within tumours in the present study, and they could
have played a part in the blood flow failure observed. How-
ever, thrombosis also could occur secondary to necrosis, or
follow stasis due to other mechanisms. The presence of236 L.J. ZWI et al.
apparently viable tumour cells between thrombosed vessels in
the superficial infiltrative tumour deposits, is evidence in
favour of thrombosis as a primary event. Thrombosis could
also explain the extension of perfusion failure into surround-
ing normal tissues seen in the fluorescent marker studies.
However, the paucity of thrombi in the necrotic VS cores is
evidence against thrombosis as the cause of perfusion failure.
The presence of macrophages and other immune effector
cells in peritoneal spheroids raises the question of their role
in mediating the FAA-induced perfusion effects. FAA has
immunostimulatory activity (Ching & Baguley, 1988, 1989)
and macrophage products share with FAA the capacity to
cause tumour necrosis (Baguley et al., 1989). This activity is
mediated, at least in part, by vascular mechanisms. Algire et
al. (1947) first showed that the anti-tumour action of
endotoxin involved vascular damage and decreased blood
flow. Tumour necrosis factor-t (TNFa), now thought to be
the major (Carswell et al., 1975), but not exclusive (North &
Havell, 1988), mediator of the endotoxin antitumour effect,
has been shown to cause tumour vessel haemorrhage and
thrombosis (Watanabe et al., 1988). However, attempts to
inhibit the antitumour effect of TNFa by blocking coagula-
tion pathways have produced variable results (Watanabe et
al., 1988; Shimomura et al., 1988). Tumour necrosis preceded
by vessel leakiness has been observed in RIF-1 and PancO2
tumours after treatment with interleukin-1 (Braunschweiger
et al., 1988). Interferon a/, injected directly into or around
erythroleukaemia cell tumours also caused tumour necrosis,
accompanied by damage to endothelial cells (Dvorak &
Gresser, 1989). The early production of mRNAs for
interferon and TNFa in vivo in response to FAA treatment
(Mace et al., 1990), argues for the participation of these
monokines in the FAA mechanism.
The fluorescent marker study used was based on that of
Trotter et al. (1989), in which each of two fluorescent dyes,
H33342 and the carbocyanin dye DiOC7(3), are injected in-
travenously at different times. These dyes stain the tumour
tissue close to those vessels which are functional at the time
of injection, allowing changes in perfusion status of indivi-
dual vessels to be observed. This technique is very sensitive
to focal, complete loss of blood flow because it compares the
pre- and post-treatment perfusion patterns in the same tissue
section (Zwi et al., 1989). H33342 is a useful first vascular
marker because of its low toxicity, diffusion characteristics
and stability in vivo (Trotter et al., 1989). However, in our
hands, DiOC7(3) showed acute toxicity at doses required for
adequate tissue fluorescence, and showed different diffusion
properties to those of H33342 (see below).
After testing several alternative fluorescent compounds, we
found that NAO functioned as a tumour vascular marker,
and was superior to DiOC7(3) in several respects. NAO
diffuses out of the vessels in vivo as does H33342, avoiding
the apparent perfusion mismatch occurring with DiOC7(3),
which only diffuses out of the vessels after the sections are
cut and mounted and requires that the vessels be transected
(Zwi et al., 1989). This allowed the use of dry sections which
are more stable than wet-mounted sections, and therefore
provide advantages for photography or quantitation by mor-
phometry. NAO also has superior aqueous solubility, and
does not show acute toxicity at doses required to mark
tumour vessels with high fluorescent intensity. Toxicity at
later times and rapid diffusion though tumour tissue in vivo
relative to H33342 (unpublished findings), did however limit
its use to that of a second label administered shortly before
sacrifice. NAO is also more subject to photo-bleaching than
DiOC7(3).
NAO is a highly fluorescent lipophilic acridine quaternary
salt which is concentrated in mitochondria, even after
osmotic shock or uncoupling of respiration (Ratinaud et al.,
1988). We can therefore exclude a direct effect of FAA on
mitochondrial metabolism or physical integrity as a reason
for failure of tumour cells in affected regions to take up this
dye, and we can thus confidently attribute this to a lack of
perfusion at the time of the second injection.
The fluorescent marker studies confirmed the distribution
of blood vessels in the VS seen in histological sections, with
the presence in all VS of a uniform outer avascular zone
surrounding vascularised tumour tissue. This confirmation
was necessary, since the presence of small or collapsed vessels
in the outer zone could not be confidently excluded on
histological sections alone. Observations in FAA-treated VS
showed a marked loss of tumour perfusion by 4 h, similar to
that seen in our previous study (Zwi et al., 1989), even
though the dose of FAA was reduced by J. In our earlier
study, EMT6 tumours not treated with FAA showed a small
loss in tumour perfusion over 4 h, but in the VS experiments
reported here we found no vessels which either opened or
closed during this period, possibly because of the smaller size
of the tumours.
In conclusion, peritoneal avascular spheroids (Lord et al.,
1979) represent an intermediate stage between spheroids
grown entirely in vitro and actual tumours, since they share
with tumours infiltration by immune effector cells. The vas-
cularised peritoneal spheroids described in this paper
represent a further intermediate stage in which a vascular
component is added. The VS tumour system has potential in
the study of the basic biology of tumour angiogenesis, drug
diffusion in the treatment of intra-cavity malignancies, and
antitumour agents thought to act by inhibition of tumour
blood flow.
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